-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Carfilzomib in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carfilzomib in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carfilzomib in Plasma Cell Neoplasm Drug Details: Carfilzomib (Kyprolis) is an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Plasma Cell Neoplasm Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bortezomib in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bortezomib in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bortezomib in Plasma Cell Neoplasm Drug Details: Bortezomib (Velcade) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RD-138 in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-138 in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-138 in Plasma Cell Neoplasm Drug Details: RD-138 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Plasma Cell Neoplasm Drug Details:...
-
Product Insights
Plasma Kallikrein – Drugs In Development, 2023
Global Markets Direct’s Plasma Kallikrein provides in depth analysis on Plasma Kallikrein targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasma Kallikrein targeted therapeutics development and features...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For Hodgkin Lymphoma, Non Hodgkin’s Lymphoma And Plasma Cell Neoplasm in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For Hodgkin Lymphoma, Non Hodgkin's Lymphoma And Plasma Cell Neoplasm in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lenalidomide in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenalidomide in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenalidomide in Plasma Cell Neoplasm Drug Details: Lenalidomide (Revlimid) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CHM-0201 in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CHM-0201 in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CHM-0201 in Plasma Cell Neoplasm Drug Details: CHM-0201 is under development...